Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.67B | 2.69B | 2.63B | 2.59B | 2.36B | 2.12B |
Gross Profit | |||||
1.47B | 1.49B | 1.43B | 1.43B | 1.32B | 1.13B |
EBIT | |||||
655.51M | 674.00M | 672.76M | 702.36M | 615.13M | 349.55M |
EBITDA | |||||
797.34M | 810.58M | 786.74M | 771.62M | 703.55M | 446.95M |
Net Income Common Stockholders | |||||
452.36M | 467.28M | 487.49M | 513.10M | 454.37M | 249.54M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
130.42M | 115.95M | 115.68M | 163.46M | 299.97M | 208.29M |
Total Assets | |||||
5.87B | 6.00B | 5.25B | 3.82B | 3.79B | 3.67B |
Total Debt | |||||
2.30B | 2.32B | 1.86B | 737.86M | 815.90M | 1.11B |
Net Debt | |||||
2.16B | 2.20B | 1.75B | 574.40M | 515.92M | 897.70M |
Total Liabilities | |||||
2.99B | 3.07B | 2.65B | 1.53B | 1.63B | 1.92B |
Stockholders Equity | |||||
2.88B | 2.93B | 2.60B | 2.29B | 2.16B | 1.76B |
Cash Flow | Free Cash Flow | ||||
464.68M | 491.78M | 606.70M | 461.70M | 507.62M | 451.89M |
Operating Cash Flow | |||||
542.96M | 556.19M | 641.28M | 513.13M | 545.93M | 502.42M |
Investing Cash Flow | |||||
-852.95M | -844.40M | -1.44B | -222.76M | -33.17M | -194.11M |
Financing Cash Flow | |||||
307.40M | 294.50M | 750.51M | -416.01M | -422.91M | -251.53M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $11.77B | 23.79 | 19.27% | 0.87% | 6.99% | 23.25% | |
78 Outperform | $16.21B | 25.41 | 18.59% | 0.97% | -0.42% | 3.23% | |
78 Outperform | $11.99B | 27.29 | 15.54% | 1.42% | 1.98% | -7.66% | |
74 Outperform | $14.11B | 29.79 | 20.28% | 1.25% | -0.40% | -2.50% | |
74 Outperform | $13.54B | 28.38 | 12.73% | 1.55% | 1.66% | -17.18% | |
72 Outperform | $8.74B | 37.54 | 3.69% | 1.06% | -10.19% | ― | |
65 Neutral | $4.44B | 12.22 | 5.28% | 248.14% | 4.08% | -12.12% |
Nordson Corporation reported its fiscal second quarter 2025 results, highlighting a 5% year-over-year sales increase to $683 million, driven by strong performance in electronics systems and steady growth in nonwovens systems, precision agriculture, and medical fluid components. Despite a decrease in industrial systems sales, the company achieved an EBITDA of 32% of sales, reflecting operational excellence. The Atrion acquisition exceeded expectations, contributing to the growth. Looking ahead, Nordson anticipates third-quarter sales between $710 to $750 million, supported by strong order entry and backlog, aligning with their full-year guidance.
The most recent analyst rating on (NDSN) stock is a Buy with a $260.00 price target. To see the full list of analyst forecasts on Nordson stock, see the NDSN Stock Forecast page.
On April 28, 2025, Nordson Corporation announced a leadership transition in its Medical and Fluid Solutions segment, with Justin Hall promoted to Executive Vice President and segment leader, succeeding Stephen Lovass. Hall, who joined Nordson in 2006, has a strong track record and expertise in deploying the NBS Next growth framework, positioning the company for organic growth in multiple end markets. The transition aims to capitalize on market opportunities in the medical sector, which is driven by long-term growth factors such as an aging population and increasing healthcare spending.